Safety and efficacy of glivec prior to allografting for CML and Ph-positive ALL: European experience

被引：0
|
作者：
Deininger, MWN
Schleuning, M
Olavarria, E
Fischer, T
Nagler, A
Sayer, H
Boque, C
Volin, L
Piotelli, G
Russel, N
Wandt, H
Schanz, U
Greinix, H
Sponk, L
Sponk
Verdonck, L
Lennard, A
Wimmer, M
Hegenbart, U
Lange, T
Niederwieser, D
机构：
来源：
BONE MARROW TRANSPLANTATION | 2002年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
183
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [41] Loss of heterozygosity (LOH) for HumACTBP2 (SE33) is detected in Philadelphia (Ph)-positive and Ph-negative hematopoietic cells of some patients with Ph-positive CML
    Al-Ali, HK
    Edebmann, J
    Leiblein, S
    Mueller, C
    Hennig, E
    Bless, M
    Franke, C
    Niederwieser, DW
    BLOOD, 2005, 106 (11) : 919A - 919A
  • [42] EVALUATION OF MRD MONITORING IN PERIPHERAL BLOOD VS BONE MARROW SOURCE IN PH-POSITIVE ALL
    Attardi, E.
    Savi, A.
    Sini, D.
    Conti, C.
    Nardozza, A. M.
    Meddi, E.
    Mallegni, F.
    Ranucci, G.
    Buzzatti, E.
    Ottone, T.
    Gurnari, C.
    Divona, M.
    Cefalo, M. G.
    Locatelli, F.
    Del Principe, M. I.
    Voso, M. T.
    HAEMATOLOGICA, 2024, 109 : 85 - 86
  • [43] THE EFFICACY AND SAFETY OF GENERIC IMATINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) AFTER SWITCHING FROM GLIVEC: UPDATED DATA FROM CERRAHPASA CML COHORT
    Soysal, T.
    Eskazan, A. E.
    Sadri, S.
    Erdogan, I.
    Berk, S.
    Yalniz, F. F.
    Elverdi, T.
    Salihoglu, A.
    Ar, M. C.
    Aydin, S. Ongoren
    Baslar, Z.
    Tuzuner, N.
    Ozbek, U.
    Aydin, Y.
    HAEMATOLOGICA, 2015, 100 : 447 - 447
  • [44] Absence of deletions upstream of ABL on the derivative chromosome 9 in patients with Ph-positive ALL.
    Deininger, MWN
    Krahl, R
    Müller, C
    Hennig, E
    Niederwieser, D
    BLOOD, 2000, 96 (11) : 187B - 187B
  • [45] Is the Distribution of Gene Copy Number Alteration in Ph-Positive B-ALL Different From Ph-Negative B-ALL?
    Leons, Gadha K.
    Sharma, Preity
    Gupta, Sanjeev Kumar
    Bakhshi, Sameer
    Gupta, Ritu
    Gajendra, Smeeta
    Roy, Anita
    Sahoo, Ranjit Kumar
    Pushpam, Deepam
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S253 - S254
  • [46] RELATIONSHIP BETWEEN CHRONIC PHASE CML, LYMPHOID ACUTE PHASE OF CML AND PH1 POSITIVE ALL
    GALE, RP
    DREAZEN, O
    CANAANI, E
    EXPERIMENTAL HEMATOLOGY, 1988, 16 (06) : 475 - 475
  • [47] SAFETY AND EFFICACY OF FLUDARABINE AND PK-TARGETED INTRAVENOUS BUSULFAN BEFORE ALLOGRAFTING FOR ADULT ALL
    Anasetti, C.
    Santarone, S.
    Alsina, M.
    Ayala, E.
    Field, T.
    Kharfan-Dabaja, M.
    Ochoa, L.
    Perez, L.
    Perkins, J.
    Raychaudburi, J.
    Sullivan, D.
    Fernandez, H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2009, 15 (02) : 64 - 64
  • [48] Successful autologous stem cell transplantation in Ph-positive ALL patient with refractory invasive pulmonary aspergillosis
    Lisukov, I
    Sizikova, S
    Kulagin, A
    Kruchkova, I
    Gilevich, A
    Klimova, I
    Kozlov, V
    BONE MARROW TRANSPLANTATION, 2004, 34 (06) : 559 - 560
  • [49] Glivec treatment for Ph-positive (Ph+) leukemias who relapsed before or after allogeneic stem cell transplantation (ASCT) with intensive monitoring of minimal residual disease (MRD)
    Yamada, M
    Miyamura, K
    Sasaki, O
    Kamcoka, J
    Meguro, K
    Sasaki, T
    EXPERIMENTAL HEMATOLOGY, 2002, 30 (06) : 135 - 135
  • [50] DASATINIB ALONE CAN ALLOW MRD NEGATIVE COLLECTION IN PATIENTS WITH PH-POSITIVE ALL: A CASE REPORT
    Cimminiello, M.
    Pizzuti, M.
    Vertone, D.
    Attolico, I.
    Poggiaspalla, M.
    Magaldi, A.
    Grippo, T.
    Musto, C.
    Olivieri, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 465 - 466
12345